The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors By Ji-Hyun Lee SK pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two new viral vector platforms that are expected to save the time and cost of …
SK pharmteco is attending BOS Manchester 2023 Pharma R & D Outsourcing November 28 – 29, 2023 at Charter Suite, Manchester Central. Visit Brian Fairley and Pedro Couto Rosado at stand 4. Learn more about the event here.
Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use Evry-Courcouronnes (near Paris), France, November 7, 2023 – Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), today launches AAVelocityTM, …
"*" indicates required fields
